<DOC>
	<DOCNO>NCT03056612</DOCNO>
	<brief_summary>The aim study ass prospectively critical period prior development Acute-on-Chronic Liver Failure ( ACLF ) ( 1 ) , uncover mechanistic pathophysiological process associate development clinical course ACLF ( 2 ) identify precipitate event ACLF ( 3 ) .</brief_summary>
	<brief_title>Predicting Acute-on-Chronic Liver Failure Cirrhosis ( PREDICT ) Study</brief_title>
	<detailed_description>1 . This International-European , investigator-initiated , multicenter , prospective , observational study perform center belong European Foundation Study Chronic Liver failure ( EF-CLIF ) -European Association Study Liver ( EASL ) -EASL-CLIF Consortium . 2 . The population patient would include ca . 1,200 cirrhotic patient twelve-months period . These patient admitted/referred study center acute decompensation ( AD ) cirrhosis ( ascites , overt encephalopathy , GI-hemorrhage , new onset non-obstructive jaundice and/or bacterial infection ) , without ACLF ( define accord Canonic study ) hospitalization . 3 . After enrolment visit , patient stratify two group : Group 1 patient high risk ACLF development ( CLIF-C AD score ≥ 60 ) Group 2 patient low risk ACLF ( CLIF-C AD score &lt; 60 ) . The whole cohort follow 3 month , Group 1 follow closely . Development ACLF end-point case final visit 7-10 day ACLF development plan . Data liver transplantation , mortality cause mortality 3 month , 6 month 12 month collect whole cohort . 4 . Prospective collection biological material performance ancillary study investigate predictor development pathogenesis ACLF . Specific goal study : - To identify early clinical predictor , biomarkers , mechanism precipitate event critical period prior involved development clinical course ACLF ( special emphasis medical trajectory drug history ) patient admitted/referred study center acute decompensation cirrhosis ( ascites , GI-hemorrhage , overt encephalopathy , new onset non-obstructive jaundice and/or bacterial infection ) chronological relationship event occurrence dynamic ACLF development . - To develop score predict ACLF development ( CLIF-PREDICT score ) ass 28-day , 90-day , 6-month 1-year all-cause mortality cirrhotic patient acute AD , without ACLF . - To serve core ( hub ) study prospective ancillary study regard diagnosis , prognosis pathogenesis AD ACLF . Main endpoint - Assessment critical period prior ACLF development - Characterization mechanism responsible ACLF development - Predictors clinical course dynamic ACLF evolution mortality . - Identification role precipitate event ACLF development . - To elaborate CLIF-PREDICT score 2 . Secondary endpoint - Prospective core ancillary study investigate pathogenesis ACLF . - Role chronic systemic inflammation development severity ACLF - Role microbiota development severity ACLF - Role Drug-induced-liver-injury ( DILI ) development severity ACLF - Role health trajectory comorbidities development severity ACLF - Prospective ancillary study investigate pathogenesis ACLF .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>The patient admitted/referred study center AD cirrhosis ( ascites , overt encephalopathy , new onset nonobstructive jaundice , GIhemorrhage and/or bacterial infection ) , without ACLF ( define accord CANONIC study ) study inclusion . 1 . Presence ACLF inclusion ; 2 . Pregnancy ; 3 . Age &lt; 18 year ; 4 . Patients acute subacute liver failure without underlying cirrhosis ; 5 . Patients cirrhosis develop decompensation postoperative period follow partial hepatectomy ; 6 . Evidence current malignancy except nonmelanocytic skin cancer hepatocellular carcinoma within Milan criterion ; 7 . Presence history severe extrahepatic disease ( e.g. , chronic renal failure require hemodialysis , severe heart disease ( NYHA &gt; II ) ; severe chronic pulmonary disease ( GOLD &gt; III ) , severe neurological psychiatric disorder ) ; 8 . HIVpositive patient 9 . Previous liver transplantation 10 . Admission/referral 72 hour inclusion 11 . Patients decline participate provide prior write informed consent document evidence patient legal surrogate decision maker appear unlikely patient regain consciousness sufficient ability provide delay informed consent ; 12 . Physician´s denial ( e.g . investigator considers patient follow protocol schedule ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>